SCHEDULE 13D
This Amendment No. 11 (“Amendment No. 11”), being filed jointly by CBI USA, Inc. (“CBI USA”) and DGP Co., Ltd. (“DGP”, and together with CBI USA, the “Reporting Persons”), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on June 1, 2022 (the “Initial Schedule 13D” and together with Amendment No. 1 thereto filed with the SEC on October 31, 2022 (“Amendment No. 1”), Amendment No. 2 thereto filed with the SEC on December 5, 2022 (“Amendment No. 2”), Amendment No. 3 thereto filed with the SEC on December 19, 2022 (“Amendment No. 3”), Amendment No. 4 thereto filed with the SEC on January 23, 2023 (“Amendment No. 4”), Amendment No. 5 thereto filed with the SEC on February 13, 2023 (“Amendment No. 5”), Amendment No. 6 thereto filed with the SEC on March 3, 2023 (“Amendment No. 6”), Amendment No. 7 thereto filed with the SEC on May 1, 2023 (“Amendment No. 7”), Amendment No. 8 thereto filed with the SEC on May 17, 2023 (“Amendment No. 8”), Amendment No. 9 thereto filed with the SEC on June 28, 2023 (“Amendment No. 9”), and Amendment No. 10 thereto filed with the SEC on August 8, 2023 (“Amendment No. 10”), the “Schedule 13D”) by CBI USA, and, with respect to Amendment No. 9 and Amendment No. 10, DGP, with respect to the Common Stock, par value $0.0001 per share, of Exicure, Inc. (“Exicure” or the “Company”). This Amendment No. 11 amends Items 4, 5, 6, and 7 to the extent set forth below.
Item 4. Purpose of the Transaction
Item 4 is supplemented as follows:
The Reporting Persons believe that, as a result of the changes to the composition of the Company’s board of directors in August and September of 2023, the board appropriately represents their interests as substantial stockholders and the interests of all stockholders of the Company. At this time, the Reporting Persons expect to continue to work with the board to seek financing and attempt to cure outstanding deficiencies with Nasdaq listing requirements and SEC reporting requirements.
Item 5. Interest in Securities of the Issuer
Item 5 is supplemented as follows:
On February 29, 2024, in connection with the DGP Sale (as reported in Item 6), DGP transferred its interest in 340,000 shares of Common Stock to OverdigmK. As a result, as of February 29, 2024, DGP beneficially owns (with sole voting power) 3,060,000 shares of Common Stock representing 35.4% of the outstanding shares of Common Stock, and CBI USA beneficially owns (with sole voting and dispositive power) 818,299 shares of Common Stock representing 9.5% of the outstanding shares of Common Stock. The Reporting Persons as a group beneficially own 44.8% of the outstanding shares of Common Stock as of such date. The percentage ownerships are based on 8,648,307 shares outstanding as reported in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2023.